Not quite ... screening does not equal enrolment.
And the study started in July 2019 so a number of patients must have been screened before paxalisib was included in the study in 2021.
Unless I misunderstand the study design, which is possible, it has 3 investigational study arms and 1 control arm.
The VAL-083 may end up with more patients as it also includes methylated patients.
For every 4 patients enrolled with either new, unmethylated GBM or recurrent GBM, I’d expect 1 patient in the paxalisib arm.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia commences recruitment to GBM AGILE
Ann: Kazia commences recruitment to GBM AGILE, page-12
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online